ArticleFrontiers in oncology2026

Survival benefit of neoadjuvant chemotherapy in HR+/HER2- early breast cancer stratified by luminal B status and clinical risk: a real-world cohort study in a Chinese population.

Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.